Stephens Inc. AR Grows Position in Boston Scientific Corporation $BSX

Stephens Inc. AR lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 92.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,880 shares of the medical equipment provider’s stock after buying an additional 10,034 shares during the period. Stephens Inc. AR’s holdings in Boston Scientific were worth $2,039,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. FWL Investment Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth approximately $26,000. Sound Income Strategies LLC increased its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Steph & Co. purchased a new position in Boston Scientific during the third quarter worth approximately $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific during the third quarter worth $25,000. Finally, Kilter Group LLC purchased a new stake in Boston Scientific in the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $88.13 on Friday. The company’s 50 day simple moving average is $96.90 and its 200-day simple moving average is $100.29. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a market capitalization of $130.65 billion, a price-to-earnings ratio of 47.13, a price-to-earnings-growth ratio of 1.56 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 93,095 shares of company stock worth $9,305,450. 0.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BSX. Robert W. Baird lifted their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Citigroup reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Wednesday. Evercore ISI set a $112.00 target price on shares of Boston Scientific in a report on Monday, January 5th. The Goldman Sachs Group restated a “buy” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, January 9th. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $123.89.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.